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1. New Board Member Announcement
On May 18, 2004, Governor Mitt Romney appointed Steven Bud-
ish to serve a fi ve-year term as a public member of the Massachusetts 
Board of Registration in Pharmacy. Mr Budish is an avid pilot and 
chief executive offi cer of a large dental clinic in Worcester, MA.
2. Donna Horn President of NABP
At the National Association of Boards of Pharmacy® (NABP®)
100th Annual Meeting and Centennial Celebration in April, Donna 
Horn, RPh, past president of the Massachusetts Board, was elected 
100th president of NABP. Following a very busy year as president 
of NABP, Donna will become chairperson of NABP’s Executive 
Committee for the period of 2005-2006.
3. From the President’s Desk
James T. DeVita, RPh, President
It is our mission at the Board of Pharmacy to promote, preserve, 
and protect the health, safety, and welfare of the citizens of the 
Commonwealth by fostering the delivery of quality pharmaceuti-
cal care. To accomplish this mission, the Board must assume a 
leadership role in regulating the practice of pharmacy and act in 
accordance with the highest standards of ethics, accountability, 
effi ciency, effectiveness, and open communication.
The theme of this month’s Newsletter is patient safety and 
dispensing accuracy. Promoting patient health and safety through 
accurate dispensing are of utmost importance to pharmacists. To 
achieve these goals, we must continuously seek to improve our 
profession and how we deliver our services. Every pharmacist and 
pharmacy should have the desire to persistently monitor, assess, and 
improve their practice and practice setting. Many pharmacists and 
pharmacies have embraced quality and have structured programs 
well underway; others are in the formative stages.
Safety improvement and preventative measures can take on 
many forms: workfl ow, technology, lighting, education, training, 
and staffi ng. Two of the simplest preventative measures are com-
munication and awareness. 
This month, we bring focus to two important safety issues: coun-
terfeit drugs and look-alike/sound-alike drugs. The most effective 
way to address each of these concerns is to raise awareness and 
communicate an understanding as to the subtle nature of these chal-
lenges. The Board has developed and published guidelines to assist 
you and your pharmacy staff in managing these and other issues. 
Visit our Web site and review the section on Best Practices.
4. Best Practice Recommendation of the Month 
Addresses Counterfeit Drugs
In the April 2004 Newsletter the Board wrote, 
On February 18, 2004, United States Department of Health and 
Human Services Secretary Tommy G. Thompson, Food and 
Drug Administration (FDA) Commissioner Mark McClellan, 
and NABP Executive Director/Secretary Carmen A. Catizone, 
MS, RPh, DPh, held a joint press conference to announce 
FDA’s Task Force Report on counterfeit drugs, “Combating 
Counterfeit Drugs” (www.fda.gov/oc/initiatives/counterfeit/
report02_04.html). NABP and FDA have joined forces in 
dealing with this emerging threat and NABP has developed 
new model regulations for the licensing of drug wholesalers 
that NABP and FDA are asking member boards of pharmacy 
to adopt. These model regulations will require appropriate 
background checks of key employees and electronic tracking 
requirements by 2007, called “pedigrees,” which will trace 
the movement of prescription drugs from manufacture to 
dispensing. NABP will also develop a clearinghouse of 
information on these wholesalers and has provided a list 
of drugs most suspected of being copied by clandestine 
operations. For further information, visit NABP’s Web site at 
www.nabp.net.
The Board also described the 21 Best Practice Recommendations 
developed in 2003, which the Board believes may assist in reducing 
medication errors, improving the quality of drug delivery, and optimizing 
patients’ outcomes (these recommendations may be found on the Board’s 
Web page at www.state.ma.us/reg/boards/ph/misc/bprac.htm). 
In response to recent issues regarding counterfeit drugs fi nding 
their way into the marketplace, the Board voted to adopt a best 
practice recommendation for pharmacies regulated by the Board.
Best Practice Recommendation #22 – Develop and implement 
written policies and procedures regarding the receipt, storage, 
and security of controlled substances. 
Recommended Actions:
 Visually examine all deliveries promptly on receipt to identity 
contents and determine if any contaminated, damaged, 
misbranded, expired, and/or suspected counterfeit drugs or 
devices are included in the shipment. 
 Quarantine any drugs or devices found to be unacceptable for 
further examination and determination. 
 Inspect medication during fi nal verifi cation to assure product 
accuracy and integrity. 
 Request wholesalers to certify that all medications delivered 
to the pharmacy, not accompanied by a pedigree, are 
purchased directly from the manufacturer. 
 Report suspected counterfeit medications to MedWatch 
(the FDA safety information and adverse event reporting 
program), the Board, and appropriate law enforcement 
authorities within three business days. 
 Educate consumers about the risks of counterfeit medications: 
 Encourage consumers to promptly consult with health care 
professionals if they suspect that their medication is counterfeit. 
DEA Introduces Pharmacy Theft 
Prevention Program
In response to increasing theft and armed robberies against 
pharmacies, DEA’s Offi ce of Diversion Control has introduced 
the Pharmacy Theft Prevention Program. The program is based 
on a previous initiative that was developed during the late 1970s 
and early 1980s when there was a similar unprecedented spike in 
the occurrence of thefts and robberies against pharmacies.
The intent of the program is to provide education and in-
creased communication to pharmacists and pharmacy staff to 
prevent pharmacy theft. The program includes collaboration and 
participation from law enforcement, regulators including state 
pharmacy boards, state and federal prosecutors, the media, and 
the public along with the pharmacy community. The Pharmacy 
Theft Prevention Program will also provide a means to maximize 
the use of limited resources available to law enforcement to 
address, minimize, and eliminate pharmacy thefts in areas that 
experience such problems.
Staff members of the DEA’s Offi ce of Diversion Control have 
begun a series of regional meetings to promote the program to 
DEA Diversion fi eld elements, state pharmacy boards, and lo-
cal pharmacy associations. To implement the program in your 
community, or to obtain more information regarding the program 
and its operation, call DEA Headquarters, Offi ce of Diversion 
Control, Liaison and Policy Section, at 202/307-7297.
Concentrated Morphine Solutions and Serious 
Medication Errors 
This column was prepared by the Institute for Safe Medication 
Practices (ISMP). ISMP is an independent nonprofi t agency that 
works closely with United States Pharmaco-
peia (USP) and FDA in analyzing medication 
errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and oth-
er practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gath-
ers expert opinion about prevention measures, 
and publishes its recommendations. If you would like to report 
a problem confi dentially to these organizations, go to the ISMP 
Web site (www.ismp.org) for links with USP, ISMP, and FDA. 
Or call 1-800/23-ERROR to report directly to the USP-ISMP 
Medication Errors Reporting Program. ISMP address: 1800 
Byberry Rd, Huntingdon Valley, PA 19006. Phone: 215/947-
7797. E-mail: ismpinfo@ismp.org. 
According to a recent newspaper report, a 91-year-old man 
being treated for a mild heart attack was mistakenly given a 
100-mg dose of ROXANOL™ (concentrated morphine solu-
tion) instead of 5 mg as prescribed. The error may have con-
tributed to the patient’s death the following day. Last fall, Elan 
Pharmaceuticals (the manufacturer of Roxanol at the time; 
aaiPharma recently acquired the product from Elan) issued a 
safety alert warning about deaths from accidental overdoses 
(www.fda.gov/medwatch/SAFETY/2003/roxanol.htm). Most 
overdoses involved morphine solutions that were mistakenly 
ordered, dispensed, and labeled by volume (mL), not milli-
grams. For example, in some cases, patients received 5 mL of 
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FDA Issues Final Rule Prohibiting the Sale of 
Ephedra Supplements
On February 6, 2004, Food and Drug Administration (FDA) 
announced the issuance of a fi nal rule prohibiting the sale of di-
etary supplements containing ephedrine alkaloids (ephedra). 
At the end of last year, FDA issued letters to manufacturers 
who market ephedra-containing supplements, informing them 
of the upcoming rule. FDA also urged consumers to stop using 
ephedra-containing dietary supplements immediately. Studies 
show that ephedra-containing dietary supplement have adverse 
effects on the cardiovascular and central nervous systems includ-
ing high blood pressure, heart palpitations, tachycardia, stroke, 
and seizures. FDA has linked at least 155 deaths with the use of 
dietary supplements containing ephedra.
For more information, including a Web link to the fi nal 
rule, visit the following Web site: www.fda.gov/bbs/topics/
NEWS/2004/NEW01021.html.
The fi nal rule became enforceable on April 12, 2004. Cali-
fornia, Illinois, and New York were the fi rst states to ban the 
sale of ephedra. 
DEA Issues Clarifi cation of the Exemption 
of Sales of Pseudoephedrine and 
Phenylpropanolamine 
In attempts to clarify existing laws and regulations regarding 
the over-the-counter (OTC) sale of pseudoephedrine and phen-
ylpropanolamine, Drug and Enforcement Administration (DEA) 
issued an interpretive rule this past January. This interpretive 
rule does not change any of DEA’s regulations, nor will it have 
an impact on individual retail customers of such products who 
have been purchasing them from retailers that have been properly 
following DEA’s regulations.
Specifi cally, the interpretive rule emphasizes that sales transac-
tions of ordinary OTC pseudoephedrine and phenylpropanolamine 
products (“safe harbor” products) are exempt from being regulated 
transactions as long as each transaction is below the 9-gram thresh-
old to an individual for legitimate medical use. Apparently, some 
retail distributors have misinterpreted current DEA regulations and 
believe that they may sell as much “safe harbor” pseudoephedrine 
and phenylpropanolamine to any person for any purpose as often 
as that person wishes to make a purchase. The DEA interpretative 
rule clearly dispels that belief.
Currently, retail distributors of ordinary OTC pseudoephedrine 
and phenylpropanolamine products are exempt from registering 
with DEA as a distributor of List I chemicals and complying with 
the record keeping and other regulatory requirements as long as indi-
vidual transactions for legitimate personal medical use remain below 
the 9-gram threshold (in packages of not more than 3 grams). 
To obtain more information, please visit DEA’s Diversion 
Control Program Web site, www.DEAdiversion.usdoj.gov.
Note: Although most products containing phenylpropanol-
amine were discontinued pursuant to the action of FDA in No-
vember 2000, there remains some legitimate veterinary uses for 
phenylpropanolamine that will ensure some level of its continued 
production and availability. Therefore, these products are subject 
the existing DEA regulations and this interpretive rule.
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Roxanol 20 mg/mL (100 mg) instead of the prescribed 5 mg. 
The newspaper report did not describe how this most recent er-
ror happened; however, it mentioned that Roxanol 100 mg had 
been given instead of 5 mg, pointing once again to the scenario 
described in the recent safety alert from Elan. 
Several manufacturers distribute morphine solution in differ-
ent formulations, primarily labeled (and listed in drug references) 
in mg/mL (eg, 20 mg/mL) or mg/5 mL (eg, 100 mg/5 mL, 20 
mg/5 mL). When concentrated morphine is stored in pharmacies 
or in patient care areas in hospitals or long-term care facilities, 
it is often kept next to conventional concentrations. Thus, it is 
easy to confuse these products and dosage strengths. Also, some 
physicians have prescribed the medication in terms of mL instead 
of mg, which has led to errors because multiple concentrations 
exist. Because we continue to hear about these tragic overdoses, 
we make these recommendations to reduce the risk of errors with 
concentrated morphine products:  
 If you consult with nursing homes or hospitals, avoid stock-
ing concentrated morphine solutions in patient units when 
possible, including the emergency department. Keep in mind 
that the drug is used primarily to treat chronic pain.
 Dispense concentrated solutions only when ordered for 
specifi c patients who require higher-than-usual doses due 
to severe chronic pain.
 Affi x an auxiliary label to the morphine concentrate bottle to 
warn about its high concentration and segregate the solution 
from the other concentrations.   
 Working with local physicians, purchase and dispense 
concentrated solutions in dropper bottles (available from at 
least two manufacturers) to help prevent dose measurement 
errors and differentiate the concentrated product from the 
conventional products. For patients in hospitals or long-
term care, dispense concentrated solutions in unit doses 
whenever possible. 
 Educate others to never prescribe or dispense liquid medica-
tions without the dose specifi ed in milligrams.  
 Educate staff about the risk of morphine errors and develop 
guidelines to promote its safe use.
 Manufacturers should standardize the way strength is ex-
pressed on labels, preferably in terms of mg/mL for all forms. 
This would improve clarity when comparing product labels 
(eg, it is easier to differentiate 4 mg/mL and 20 mg/mL; 
harder to differentiate 20 mg/mL and 20 mg/5 mL).
Finally, we disagree with Elan’s suggestion in its recent 
safety alert for prescribers to include the desired concentration 
of morphine along with the patient’s dose in milligrams and the 
corresponding volume (eg, Roxanol 10 mg/5 mL, give 10 mg [5 
mL] prn pain). Listing the desired concentration could actually 
lead to confusion and errors. If the prescribed concentration is 
not available and a different concentration is substituted, the 
prescriber’s directions regarding the volume to administer would 
no longer apply. Yet, if these directions remain on a medication 
administration record, or a prescription bottle, the wrong dose 
could be administered.
NABP Releases Updated Model Rules for the 
Licensure of Wholesale Distributors
On February 20, 2004, the National Association of Boards of 
Pharmacy® (NABP®) released the updated Model Rules for the 
Licensure of Wholesale Distributors. The updated Model Rules, 
part of the Model State Pharmacy Act and Model Rules of the 
National Association of Boards of Pharmacy, were provided to 
assist state boards of pharmacy in maintaining the integrity of 
the United States medication distribution system through the 
regulation of wholesale distributors. The updated Model Rules 
are the result of a concerted effort between NABP and other 
representatives from pharmacy, government, and the wholesale 
distributor industry to protect the public from the ill effects of 
counterfeit drugs and devices.
In addition to stricter licensing requirements such as criminal 
background checks and due diligence procedures prior to whole-
sale distribution transactions, the Model Rules mandate specifi c 
drug pedigree requirements for products that are particularly 
prone to adulteration, counterfeiting, or diversion. These prod-
ucts, as defi ned in the updated Model Rules, are designated as 
the “Specifi ed List of Susceptible Products.” Also, the updated 
Model Rules introduce the position of “Designated Representa-
tive.” The “Designated Representative” of a wholesale distributor 
is the person who is actively involved in and aware of the actual 
daily operation of the Wholesale Distributor.
The Model Rules for the Licensure of Wholesale Distributors 
along with the National List Specifi ed List of Susceptible Products 
can be downloaded from NABP’s Web site, www.nabp.net.
New Bar Code Requirements Aim to Reduce 
Risk of Medication Errors
In late February, FDA issued the fi nal rule Bar Code Label Re-
quirements for Human Drugs Products and Biological Products. 
This fi nal rule requires the inclusion of linear bar codes on most 
prescription drugs and certain OTC drugs. Each bar code must, 
at minimum, contain the drug’s National Drug Code number, 
but companies are encouraged to include additional information 
such as the product’s lot number and expiration date. For blood 
and blood products used in a transfusion, the fi nal rule also 
requires the use of machine-readable information in a format 
approved for use by FDA. The machine-readable information 
must include, at a minimum, the facility identifi er, the lot number 
relating to the donor, the product code, and information on the 
donor blood type.
FDA is hoping that the bar code rule will encourage the wide-
spread adoption of advanced information systems that, in some 
institutions, have reduced medication errors by 85%.
FDA expects that, with full implementation, the linear bar 
codes will result in more than 500,000 fewer adverse events over 
the next 20 years and a 50% reduction in medication errors that 
would otherwise have occurred upon dispensing or administra-
tion. New medications covered by the rule must comply within 
60 days of their approval and previously approved medications 
and blood/blood products must comply within two years.
More information including a link to the fi nal rule is available 
on FDA’s Web site at www.fda.gov/oc/initiatives/barcode-sadr.
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 Remind consumers to be aware of noticeable differences in 
their medications or packaging and the occurrence of any 
adverse events. 
 Alert consumers of the important role pharmacists play in 
identifying, reporting, and responding to counterfeit drug events. 
 Advise consumers to make online medication purchases 
from pharmacies that have obtained the Verifi ed Internet 
Pharmacy Practice Sites™ Seal from NABP. 
 Maintain records of counterfeit reports from manufacturers 
and other sources for a minimum three-year period.
 Consult NABP’s “National Specifi ed List of Susceptible Products” 
available for reference at www.nabp.net and the Board’s Web site 
under “Board News” at www.mass.gov/reg/boards/ph.
5. Mix-ups in Zantec/Zyrtec 
By Karen Ryle and Donna Horn
In Massachusetts, as well as other parts of the country, there have 
been numerous errors that have occurred in the pediatric population 
where Zantac® (ranitidine) syrup (Glaxo Wellcome) has been pre-
scribed but Zyrtec®* (cetirizine) syrup (Pfi zer) has been dispensed. 
Zantac is an H2 receptor blocker and Zyrtec is an H1 antihistamine. 
Although these medications do not have overlapping dosage strengths, 
both are available in the syrup dosage form: Zantac as 150 mg/10 mL 
and Zyrtec as 5 mg/5 mL. Since a different company manufactures 
each drug, the container labels look dissimilar. However, the syrups of 
both drugs are available in 480 mL amber glass bottles. Zyrtec syrup 
is also available in a 120 mL bottle. The proprietary names look and 
sound alike, increasing the potential for medication errors.
Errors occurred most frequently in patients ranging in ages from 
seven days to 15 months. In one case, a 12-month-old male patient was 
prescribed 120 mL of Zantac syrup but was given 120 mL of Zyrtec. 
The error occurred when the incorrect stock bottle of Zyrtec syrup was 
chosen by the technician and poured into the dispensing bottle labeled 
as Zantac. The mother noticed that the baby became “violently ill,” 
but the doctor did not fi nd any serious injury after examining the baby. 
In another case, a 15-month-old patient was given Zyrtec instead of 
Zantac for six weeks before the error was discovered. The patient’s 
refl ux-induced sinusitis continued until the error was corrected. Other 
patients experienced sleep disturbances, increased thirst, decreased 
appetite, diarrhea, vomiting, and weight loss as a result of the errors. 
Thankfully, none of the symptoms caused serious harm to patients. 
Safe Practice Recommendation
 Separate stock bottles of Zantac and Zyrtec syrups in pharmacy 
dispensing areas and any other areas in the health care facility 
where the drugs are stored* (eg, automated dispensing cabinets).
 Encourage prescribers to include the drug’s indication to 
differentiate these look-alike drug names and reduce the risk 
of selecting the wrong drug due to poor handwriting.* 
 As with all liquid oral medications, physicians should include 
the desired mg/mL concentration to guide proper drug 
selection, especially since the drug concentrations differ.* 
 The dose should also be expressed in mg, not just volume (mL 
or teaspoonfuls). Place reminders on stock bottles and install 
pharmacy computer alerts to advise staff of the risk for errors.* 
 It is also helpful to warn patients about the risk of confusing 
these two products so they can detect possible errors when 
fi lling prescriptions. 
 As a fi nal check, immediately before the patient or caregiver 
leaves the pharmacy department with the fi lled prescription, open 
the bottle and sniff the liquid. Does it smell like mint? If so, then it 
must be Zantac. What does the label indicate it is supposed to be?
*Institute for Safe Medication Practices. Action needed to pre-
vent dangerous Zyrtec-Zyprexa mix-ups. ISMP Medication Safety 
Alert! Volume 5, Issue 22, November 1, 2000.
*Similar sound-alike, look-alike mix-ups have occurred with 
Zyrtec and Zyprexa® tablets – be mindful.
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